Calidi Biotherapeutics (CLDI) Competitors $0.65 -0.05 (-6.53%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.62 -0.03 (-3.85%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CLDI vs. PYRGF, IGMS, ABOS, PYXS, AVTE, GNTA, MNOV, CRBP, CLLS, and ASRTShould you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include PyroGenesis Canada (PYRGF), IGM Biosciences (IGMS), Acumen Pharmaceuticals (ABOS), Pyxis Oncology (PYXS), Aerovate Therapeutics (AVTE), Genenta Science (GNTA), MediciNova (MNOV), Corbus Pharmaceuticals (CRBP), Cellectis (CLLS), and Assertio (ASRT). These companies are all part of the "pharmaceutical products" industry. Calidi Biotherapeutics vs. PyroGenesis Canada IGM Biosciences Acumen Pharmaceuticals Pyxis Oncology Aerovate Therapeutics Genenta Science MediciNova Corbus Pharmaceuticals Cellectis Assertio Calidi Biotherapeutics (NYSE:CLDI) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, community ranking, valuation, profitability, dividends and risk. Does the MarketBeat Community favor CLDI or PYRGF? Calidi Biotherapeutics and PyroGenesis Canada both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformCalidi BiotherapeuticsN/AN/APyroGenesis CanadaN/AN/A Which has more volatility and risk, CLDI or PYRGF? Calidi Biotherapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. Which has preferable earnings and valuation, CLDI or PYRGF? PyroGenesis Canada has higher revenue and earnings than Calidi Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalidi Biotherapeutics$50K344.03-$29.22MN/AN/APyroGenesis Canada$9.14M7.35-$21.12M-$0.06-6.00 Is CLDI or PYRGF more profitable? Calidi Biotherapeutics has a net margin of 0.00% compared to PyroGenesis Canada's net margin of -115.14%. Company Net Margins Return on Equity Return on Assets Calidi BiotherapeuticsN/A N/A -344.45% PyroGenesis Canada -115.14%N/A -60.81% Do analysts prefer CLDI or PYRGF? Calidi Biotherapeutics presently has a consensus price target of $15.00, suggesting a potential upside of 2,207.69%. Given Calidi Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Calidi Biotherapeutics is more favorable than PyroGenesis Canada.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00PyroGenesis Canada 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor CLDI or PYRGF? In the previous week, Calidi Biotherapeutics had 1 more articles in the media than PyroGenesis Canada. MarketBeat recorded 4 mentions for Calidi Biotherapeutics and 3 mentions for PyroGenesis Canada. Calidi Biotherapeutics' average media sentiment score of 0.37 beat PyroGenesis Canada's score of 0.22 indicating that Calidi Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Calidi Biotherapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PyroGenesis Canada 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals and insiders hold more shares of CLDI or PYRGF? 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 24.3% of Calidi Biotherapeutics shares are owned by company insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryCalidi Biotherapeutics beats PyroGenesis Canada on 9 of the 13 factors compared between the two stocks. Remove Ads Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDI vs. The Competition Export to ExcelMetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$17.20M$3.03B$5.63B$19.40BDividend YieldN/A1.55%5.33%3.76%P/E RatioN/A29.9323.5533.04Price / Sales344.03431.51388.1926.59Price / CashN/A168.6838.1717.55Price / Book-0.283.926.894.53Net Income-$29.22M-$71.95M$3.20B$1.02B7 Day Performance-12.17%-5.68%-3.06%-1.30%1 Month Performance-26.09%-12.09%1.51%-4.04%1 Year PerformanceN/A-27.90%9.37%2.55% Calidi Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDICalidi Biotherapeutics2.204 of 5 stars$0.65-6.5%$15.00+2,207.7%N/A$17.20M$50,000.000.0038News CoverageGap DownPYRGFPyroGenesis CanadaN/A$0.40+2.5%N/A+13.7%$75.59M$9.14M-6.7590Gap UpHigh Trading VolumeIGMSIGM Biosciences4.8254 of 5 stars$1.26+5.9%$5.50+336.5%-87.2%$75.32M$2.68M-0.35190Short Interest ↓Positive NewsABOSAcumen Pharmaceuticals2.547 of 5 stars$1.24+3.3%$9.33+652.7%-70.6%$74.50MN/A-0.9020Earnings ReportAnalyst ForecastAnalyst RevisionNews CoveragePYXSPyxis Oncology1.723 of 5 stars$1.20-0.8%$9.20+666.7%-75.1%$73.91M$16.15M-1.1760AVTEAerovate Therapeutics0.7303 of 5 stars$2.55+1.2%$2.25-11.8%-91.4%$73.63MN/A-0.8520Earnings ReportNews CoverageGNTAGenenta Science3.0126 of 5 stars$4.01-3.4%$25.00+523.4%+13.6%$73.34MN/A0.007Upcoming EarningsMNOVMediciNova1.9219 of 5 stars$1.49-2.6%$9.00+504.0%+0.0%$73.08M$1M-6.4810CRBPCorbus Pharmaceuticals3.4377 of 5 stars$5.96+3.7%$59.13+892.0%-85.9%$72.90MN/A-1.2740News CoverageCLLSCellectis3.517 of 5 stars$1.31+0.8%$7.00+434.4%-52.1%$72.82M$41.51M-1.01290ASRTAssertio2.347 of 5 stars$0.76+4.7%$2.75+263.4%-27.9%$72.47M$124.96M-1.0420Positive News Remove Ads Related Companies and Tools Related Companies PyroGenesis Canada Competitors IGM Biosciences Competitors Acumen Pharmaceuticals Competitors Pyxis Oncology Competitors Aerovate Therapeutics Competitors Genenta Science Competitors MediciNova Competitors Corbus Pharmaceuticals Competitors Cellectis Competitors Assertio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CLDI) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredPartner with Elon Musk on Project Colossus… Before May 1stEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredHuge Elon-backed AI rollout begins – buy these nine stocksIf you suspect Elon Musk has an ulterior motive for coming to Washington, D.C.... You're 100% correct. ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
